Paradigm Biopharmaceuticals Ltd (PAR) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.367x

Based on the latest financial reports, Paradigm Biopharmaceuticals Ltd (PAR) has a cash flow conversion efficiency ratio of -0.367x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-7.77 Million ≈ $-5.50 Million USD) by net assets (AU$21.18 Million ≈ $14.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Paradigm Biopharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Paradigm Biopharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Paradigm Biopharmaceuticals Ltd for a breakdown of total debt and financial obligations.

Paradigm Biopharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Paradigm Biopharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Upsales Technology AB ST:UPSALE	0.114x
DIC India Limited NSE:DICIND	0.028x
Accuray Incorporated NASDAQ:ARAY	-0.228x
Do Day Dream Public Company Limited BK:DDD	-0.001x
Decibel Cannabis Company Inc V:DB	0.028x
Ultimovacs ASA OL:ULTI	-0.299x
Cato Corporation NYSE:CATO	-0.030x
Korea Electronic Certification Authority Inc KQ:041460	0.036x

Annual Cash Flow Conversion Efficiency for Paradigm Biopharmaceuticals Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Paradigm Biopharmaceuticals Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see PAR market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$21.18 Million ≈ $14.99 Million	AU$-15.99 Million ≈ $-11.32 Million	-0.755x	+72.75%
2024-06-30	AU$23.81 Million ≈ $16.84 Million	AU$-65.94 Million ≈ $-46.66 Million	-2.770x	-229.06%
2023-06-30	AU$53.68 Million ≈ $37.98 Million	AU$-45.19 Million ≈ $-31.97 Million	-0.842x	-10.60%
2022-06-30	AU$42.31 Million ≈ $29.94 Million	AU$-32.21 Million ≈ $-22.79 Million	-0.761x	-70.56%
2021-06-30	AU$78.27 Million ≈ $55.38 Million	AU$-34.93 Million ≈ $-24.71 Million	-0.446x	-378.45%
2020-06-30	AU$108.18 Million ≈ $76.55 Million	AU$-10.09 Million ≈ $-7.14 Million	-0.093x	-21.34%
2019-06-30	AU$82.81 Million ≈ $58.59 Million	AU$-6.37 Million ≈ $-4.50 Million	-0.077x	+82.28%
2018-06-30	AU$13.86 Million ≈ $9.81 Million	AU$-6.01 Million ≈ $-4.25 Million	-0.434x	-29.92%
2017-06-30	AU$13.39 Million ≈ $9.47 Million	AU$-4.47 Million ≈ $-3.16 Million	-0.334x	-4.51%
2016-06-30	AU$11.23 Million ≈ $7.95 Million	AU$-3.59 Million ≈ $-2.54 Million	-0.319x	-284.01%
2015-06-30	AU$14.46 Million ≈ $10.23 Million	AU$-1.20 Million ≈ $-851.40K	-0.083x	-102.05%
2014-06-30	AU$-151.87K ≈ $-107.45K	AU$-617.72K ≈ $-437.08K	4.068x	--

About Paradigm Biopharmaceuticals Ltd

AU:PAR Australia Biotechnology

Market Cap

$52.17 Million

AU$73.73 Million AUD

Market Cap Rank

#21738 Global

#778 in Australia

Share Price

AU$0.17

Change (1 day)

+3.03%

52-Week Range

AU$0.16 - AU$0.47

All Time High

AU$4.35